X

NGL Fine-Chem Ltd. Stock Analysis

Small Cap
Evaluated by 440 users | BSE: 524774 | NSE: |
Pharmaceuticals & Drugs
NGL Fine-chem  is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.Its business is modelled around the changing customer...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 14.05%7.46%12.78%16.47%18.51%23.88%21.1%14.06%18.07%9.74%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 35.436.155.678.988.396.399.7114153152
Y-o-Y Gr. Rt.-2.1%53.9%41.9%12%9%3.6%14%34.8%-0.7%
Adjusted EPS (Rs.) 3.91.694.738.1411.3118.4522.9218.592916.63
Y-o-Y Gr. Rt.--56.7%179.9%72.1%38.9%63.1%24.2%-18.9%56%-42.7%
Book Value per Share (Rs.) 25.9927.6932.439.7353.1271.5796.16116.61149.11163.81
Adjusted Net Profit 2.41.12.95711.414.211.517.910.3
Net Op. Cash Flow (Rs. Cr.) 4.31.40-0.37.58.49.922.48.919.6
Debt to Cash Flow from Ops 1.467.29-567.82-56.21.761.722.31.193.071.44
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
NGL Fine-Chem Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 17.6%11.5%15.1%-0.7%
Adjusted EPS 17.5%8%-10.1%-42.7%
Book Value per Share 22.725.319.49.9
Share Price 64.1% 34.9% 50.2% 215.6%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 16.236.3115.7322.5824.3729.5927.3317.4721.8210.63
Operating Profit Margin (%) 15.0110.9113.6214.2616.9322.825.5518.9721.0815.21
Net Profit Margin (%) 6.812.95.256.387.9111.8414.210.111.76.75
Debt to Equity 0.390.60.670.680.40.330.380.370.290.28
Working Capital Days 162184147138152160187198167191
Cash Conversion Cycle 65765962657481655579
Entity Percentage Holding
Promoters 73.81%
Non-Institutions 26.19%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of NGL Fine-Chem Ltd.'s performance infers:

NGL Fine-Chem Ltd. earnings have grown by 8%, whereas share price has appreciated 34.9% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of NGL Fine-Chem Ltd. share prices over the last 10 years. Here is what we found out:

NGL Fine-Chem Ltd. share price has appreciated 51.9% annually over the past ten years.

NGL Fine-chem  is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.

Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.

Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand

NGL Fine-chem  is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.

Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.

Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand the product portfolio with new products.

It has established a strong presence in global pharmaceutical companies with its commitment to competitive prices, delivery schedules, international quality standards and constant technological upgradation.

NGL Fine-chem Ltd has a strong focus on developing intellectual property as a key differentiator and as a platform for further growth up the pharma value chain. It respect intellectual property and invest in developing it as a key growth driver for the future.

Product range of the company includes:

Pharmaceutical like Diminazene Aceturate, Diminazene Diaceturate, Homidium Chloride, Nitroxynil, Clorsulon, Homidium Bromide, Parvaquone, Carprofen, Buparvaquone and Isometamidium Chloride Hydrochloride for:

  • Animal health
  • Human health
  • Intermediate- 4 Aminobenzamidine Dihydrochloride, 3 Aminobenzamidine Dihydrochloride, Ezetimibe Intermediates etc
  • Finished dosages form- Homidium Chloride Tablets, Diminazene Aceturate Granules

Achievements/ recognition

An ISO 9001:2000 accredited company

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback